

QUARTERLY REPORT

Smoltek Nanotech Holding AB

JANUARY – MARCH 2020



Smoltek Nanotech Holding AB, Q1 2020

Smoltek is a globally operating company developing process technology and concepts for applications based on carbon nanotechnology, primarily for the semiconductor industry. Smoltek's unique technology enables the production of semiconductor components with smaller form factors, higher performance and lower energy consumption.


The company protects its unique technology through an extensive and growing IP-portfolio, consisting of about 100 applied patents, of which 57 are currently granted.

The market segment in which Smoltek is primarily active is referred to as "advanced packaging" and is expected to grow at an average annual growth rate (CAGR) of 8.0 percent during the period 2018-2024 and achieve a market value of USD 43.6 billion in 2024 (source: Yole Développement Market research).

Smoltek's share is listed on the Spotlight Stock Market in Stockholm, Sweden under the short name SMOL.

CONTENT

03. Quarterly summary (Group)
04. CEO statement: First license agreement signed
05. Significant events during and after the period
06. Business and market
08. Financial report - Financial outcome
09. Financial report - Other information
10. Financial report - Income statement for the Group
11. Financial report - Balance sheet for the Group
12. Financial report - Cash flow statement for the Group
13. Financial report - Change in equity for the Group
14. Financial report - Income statement for the Parent Company
15. Financial report - Balance sheet for the Parent Company
16. Financial report - Cash flow statement for the Parent Company
17. Financial report - Change in equity for the Parent Company
18. Upcoming reports



Quarterly Summary (Group)

JANUARY - MARCH

- Net sales: SEK 384,000 (0)
- Earnings before tax: SEK -3,991 thousand (-2,741)
- Earnings per share, before dilution: SEK -0.63 (-0.52)
- Earnings per share, after possible dilution: SEK -0.59 (-0.51)
- Number of shares outstanding: 6,377,338 (5,314,450)
- Number of shares after possible exercise of warrants: 6,806,124 (5,396,210)
- Total equity: SEK 63,754 thousand (35,795)
- Cash and cash equivalents: SEK 22,818 thousand (1,893)
- Equity ratio: 93.0% (90.7%)
- First licensing agreement for capacitor technology CNF-MIM signed
- Two new patents have been granted – the IP portfolio now contains a total of 57 patents granted
- Senior executives subscribed for SEK 4.26 million in subsidiaries

REVENUES AND RESULTS FIRST QUARTER

Net sales during the period amounted to KSEK 384 (0). Operating profit was SEK -4.0 million (-2.7). Earnings per share before dilution were SEK -0.63 (-0.52). Earnings per share after possible dilution were SEK -0.59 (-0.51).

LIQUIDITY AND FINANCIAL POSITION


The company's cash and cash equivalents at the end of the period amounted to SEK 22,818,000 (1,893). Long-term interest-bearing liabilities amounted to KSEK 819 (838). The equity / assets ratio was 93.0 percent (90.7).

EQUITY AND NUMBER OF SHARES

Equity at the end of the period amounted to SEK 63,754,000 (35,795), divided into 6,377,338 shares.

EMPLOYEES

The number of employees was 12 people.



First license agreement signed

In March we achieved a milestone that we have been working very hard to reach – the first license agreement for our CNF-MIM technology that enables the production of high-performance capacitors using just a fraction of the space needed for conventional capacitors. The evaluation license agreement was signed with one of the world's largest capacitor manufacturers. In collaboration with Smoltek, they will now evaluate the technical and commercial aspects of the technology in a project that is defined from its application focus. The collaboration has already started, and it is both inspiring and valuable for our further development of the technology to work with one of the world's leading companies in this field.

This agreement is valid until August 2020 with the possibility to extend its duration. The aim is to then progress to a production license agreement for the implementation of our technology on a commercial scale. It is important to emphasize that the signed agreement is not exclusive, thus allowing us to carry out similar evaluations with other companies as well. There was a strong interest in our CNF-MIM technology before the license agreement was announced, and we now experiencing an even higher level of interest as the agreement can be seen as an important indication of the commercial potential for our CNF-MIM technology.

While Smoltek is in a stronger position than ever, we closely follow the development of the covid-19 situation. So far, we have only been affected to a limited extent. Important conferences have been postponed or cancelled, and we are of course not able to schedule any physical meetings in for example Asia and the United States.

We are however able to continue with the main parts of our business operations without any substantial difficulties. Our access to the lab facilities has not been affected so far, and we continue our dialogues with potential customers and partners just like before by utilizing online meetings. As the current restrictions seem to be transient, we are not receiving any indications that our potential customers and partners would like to take a step back or pause their ongoing discussions with us. Instead, our view is that they are just as focused as before on prepared for the future in

order to be well-prepared when the situation becomes more normal again.

Exercising of subscription warrants (TO 2)

At the end of March, senior executives and employees in Smoltek subscribed for 4.26 SEK million in shares in the operating subsidiary within the framework of an incentive program. I was one of the participants in this program, and I agree with our Chairman of the Board that the employee participation in this program is a clear indication that we as a team has a strong confidence in our technology.

I would like to take this opportunity to remind everyone that holds subscription warrants (TO 2) from the preferential rights issue that we conducted last spring to make sure to use them during the exercise period in April. The warrants entitle the holder to subscribe for shares in Smoltek until April 30 with a 30 percent discount compared to the average market price measured during a 10-day period which ended on April 16.

I hope that many of you, like myself, feel positive about the opportunity to subscribe for shares in Smoltek and thereby contribute to a strong financial platform and continued strong prospects for the future!

Anders Johansson, vd Smoltek Nanotech Holding AB



Significant events – during and after the Q1-period

Significant events during the first quarter of 2020

Smoltek ends negotiations with Imec regarding demonstration in 300mm format

On January 21, Smoltek announced that the company has ended its negotiations with the research institute Imec regarding demo production of CNF-MIM capacitors in so called 300mm format. Instead, Smoltek chooses to deepen its relations with industrial entities in the semiconductor industry, as they are deemed to be able to offer possibilities to commence demo production in a setup that more closely resembles commercial manufacturing. This is also expected to facilitate a faster path to industrialization.

Two new patent approvals

During the quarter, Smoltek received two more patent approvals. One of the patents are a part of the company's new patent family that specifically protects the CNF-MIM technology with a focus on interposers, and the other covers essential aspects of a binding film based on nanostructures. With the two new patents included, Smoltek's IP portfolio increased to a total of 57 granted patents.

Smoltek signs evaluation license agreement with leading capacitor manufacturer

On March 26, Smoltek announced that the company has signed an evaluation agreement with one of the world's largest capacitor manufacturers. The agreement will be valid until August 2020, with the possibility to extension. During this time, Smoltek's CNF-MIM technology will be evaluated from both a technical and commercial perspective in a joint project with the ambition to sign a production license agreement as a next step. The order value for this first step amounts to approximately SEK 1 million.

Postponed Annual General Meeting

Due to the current uncertainty as a result of Covid-19, the Board has decided to postpone this year's Annual General Meeting. The company will announce the Annual General Meeting not later than four weeks before the new date. However, the Annual General Meeting will be held no later than June 30, in accordance with current legislation. The Annual General Meeting was previously scheduled for May 7.

Updated information about the meeting will also be available on Smoltek's website.

Subscription for 4.26 SEK million in shares in subsidiary

On March 31, Smoltek announced that the company has received subscriptions for shares in the subsidiary Smoltek AB

totalling approx. 4.26 SEK million. The subscriptions were made through the incentive program (2017/2020:1), with subscription period 2020-02-10–2020-03-31, in which five senior executives and long-time employees participated. Smoltek's CEO Anders Johansson subscribed for over 2.3 SEK million in shares. In addition to his subscription through this program, CEO Anders Johansson owns, via company, 140,075 shares (corresponding to an ownership of approximately 2.2 percent) in the parent company Smoltek Nanotech Holding AB that is listed on Spotlight Stock Market.

The incentive program of warrants (series 2017/2020:1) was implemented before Smoltek was listed on Spotlight Stock Market, and it therefore refers to the issue of shares in the operating subsidiary Smoltek AB. However, the intention is that the listed company Smoltek Nanotech Holding AB is to continue to hold 100 percent of the ownership in this subsidiary. At the upcoming Annual General Meeting, the Board therefore intends to present a proposal for a non-cash issue where the new shares in the subsidiary will be exchanged for shares in the listed company.

Significant events after the end of the period

Trading with Smoltek's TO 2 warrants

On April 20, the exercise period for warrants of the TO 2 series, which were issued to subscribers in the company's preferential rights issue in March 2019, was initiated. The subscription price is 42.68 SEK, which was announced on April 17. The exercise period for the TO 2 warrants will last until April 30. For those who wish to sell their warrants, the last day of trading is April 28. As with Smoltek's shares, the trading with Smoltek's warrants of the TO 2 series is conducted on Spotlight Stock Market.

New evaluation agreement for the CNF-MIM technology

On April 20, it was announced that the company has signed another evaluation agreement, and this time the licensee is a leading manufacturer of passive electronic components including capacitors. The agreement covers an evaluation license where Smoltek's patented carbon nanofiber-based CNF-MIM technology is to be evaluated in a joint project. The order value for this first step amounts to approximately SEK 1 million, and the aim is for the agreement to lead to a production license agreement as the next step.

Business activities and market – overview


Overall market potential and strategy

The semiconductor industry is constantly evolving, and in recent years we have seen an increasing diversification within circuits optimized for different purposes and products. The miniaturization has gone from focusing solely on the transistor density in the silicon to the practical integration of the circuit. Advanced packaging and heterogeneous integration are terms that are commonly used when circuit internal elements are combined in a smarter way, and when stacking these elements for a more efficient overall solution. It is not only the size of the finished circuit that is reduced; better integration also provides performance and efficiency improvements.

In this area, there is considerable potential for Smoltek as the company's thin carbon nanofibers provide a significantly larger total area through the three-dimensional effect. Put in context, if you cover the surface of a Rubik's cube with Smoltek's patented carbon nanofibers, you get an actual total area of the size of a football pitch.

The company also believes that its technology can provide similar benefits in several other industries and industrial segments.

Smoltek's overall strategy is to first establish the company commercially in the billion-dollar market for advanced packaging. This is done by licensing the CNF-MIM concept for production of miniaturized capacitors suitable for integration into advanced packaging of high-performance semiconductor circuits, such as for example CPUs, GPUs or AI processors. Thereafter, the company plans to expand the business gradually, both in the semiconductor industry and in other industries and segments. Subsequently, a gradual expansion of the business is planned, both in the semiconductor industry and in other industries and segments. This allows Smoltek to take maximum advantage of its position as a pioneering technology developer in controlled growth of advanced nanostructures, both today and in the future.



Business activities and market – current position

Operations and business model

Smoltek develops process technology and concepts for applications based on carbon nanotechnology, today primarily for the global semiconductor industry. The company's unique technology enables the production of semiconductor components with less physical size, higher performance and lower energy consumption compared to today's conventional technology solutions.

The company's business model and objective is to sign license agreements for its technology – patents, know-how and applications / solutions. The first application is the CNF-MIM concept, where vertical conductive carbon nano-fibers (CNFs) provide an efficient surface by making the 3D effect immensely larger than the conventional 2D im-print. A large effective surface is a key factor in a capacitor design. The CNF-MIM concept offers a unique solution for miniaturized capacitors through an extremely low profile height, and is primarily intended for integration into miniaturized semiconductor components. This directly enables higher performance and indirectly to more energy efficient components.

Marketing strategy

Initially, Smoltek focuses on licensing its technology for CNF-MIM capacitors for integration into semiconductor components. In this market segment, the low profile height provides unique advantages. Licensing can be done to capacitor manufacturers that currently supply traditionally manufactured capacitors to this market. According to the company's assessment, this segment has the best conditions for implementing Smoltek's technology. After having established the company in this segment, Smoltek will focus on other parts of the semiconductor industry, in particular on so-called foundries (silicon manufacturers) and packaging companies that can exploit the advantages of directly integrating CNF-MIM on, for example, silicon chips or so-called interposers.

To broaden the opportunities to capitalize on the company's technology platform, Smoltek has initiated a collaboration with DC Advisory, a leading global financial advisor with expertise in industrial transactions. DC Advisory has a broad network in both the semiconductor and electronics industries as well as in other

industrial segments. The agreement contributes to an increased global presence for Smoltek and opens opportunities through strategic relationships in both new and existing application areas and industries.

IP strategy

Smoltek uses a global patent strategy to protect its technology platform in all important markets. This includes core patents as well as patent protection at application level. At present, the company has a portfolio that comprises about 100 applied patents, of which 57 are granted.

Smolteks market – focus on CNF-MIM

The semiconductor industry faces a major challenge with the expansion of new technologies such as 5G, AI and IoT – which require the development of new highly integrated technology with greatly improved computational performance and greater storage capacity in a less physical format. Simply put, it is the miniaturization in itself that enables higher performance. The key to optimization is advanced packaging or heterogeneous integration - in practice, this means tailor-made architectures for each product and application area.

In these architectures, capacitors have a crucial function, and with a considerably lower profile height compared to today's capacitors, direct performance benefits can be achieved through smarter integration possibilities.

With its extremely low-profile height, Smoltek's CNF-MIM concept is very well positioned for the market's future needs for production of integrated capacitors as well as stand-alone components for integration in the packaging process.

The market segment of advanced circuit packaging is expected to grow by an average of 8.0 percent per year during the period 2018-2024 (To a value of approximately USD 43.6 billion in 2024, Source: Yole Développement). A recent report from International Data Corporation analyzes the effects of the semiconductor market on covid-19. In its summary, IDC says that the most likely outcome of this event will generate a -6% sales reduction for the global semiconductor market by 2020.

Financial outcome

Turnover

Net sales during the first quarter amounted to SEK 384,000 (0).

Expenses

Expenses during the period were SEK 5,674,000 (2,741).

The increase compared to the previous year can in large part be attributed to a larger organization as well as continued investments in market processing.

Results

Consolidated earnings for the first three months of the year amounted to SEK -4.0 million (-2.7) after financial items.

Cash flow and financial position

Cash flow from operating activities amounted to SEK -3,960,000 (-2,903). Cash and cash equivalents at the end of the period amounted to SEK 22,818 thousand (1,893).

Liquidity and financing

As of March 31, 2020, the Group's bank balances amounted to SEK 22,818,000 (1,893). Long-term interest-bearing liabilities amounted to SEK 819,000 (838).

investments

Investments in intangible fixed assets amount to SEK 2.1 million and relate to the further development of the company's own technology. The investment in tangible fixed assets of SEK 1.0 million made in 2018 relates to advance payment on equipment to use in the company's operations at Chalmers. The total investment is estimated to amount to approximately SEK 3.0 million. However, the company is still not satisfied with the displayed functionality and has therefore not approved the system. Negotiations are ongoing with the supplier on how to solve the problem. This does not affect the company's ongoing R&D business.

Key ratios

(KSEK)

| | Q1 2020 | Q1 2019 |
|--------------------------|---------|---------|
| Return on equity | -6.3% | -7.7% |
| Return on total equity | -5.8% | -6.9% |
| Equity/assets ratio | 93.0% | 90.7% |
| Cash and cash equivalent | 616.3% | 108.0% |

Additional information

The Share

Smoltek Nanotech Holding AB has been listed on Spot-light since 2018 under the short name SMOL. As of March 31, 2020, the company had approximately 2,000 shareholders. The number of shares amounts to 6,377,338.

Warrants

Outstanding warrants as of March 31, 2020:

| | |
|-------------------------------|----------------|
| Peter Augustsson, Chairman | 81,760 |
| Gustav Brismark, Board member | 20,300 |
| Employees | 61,004 |
| Subscription warrants TO 2 | 265,722 |
| A Total of | 428,786 |

Intangible assets

The company's most important assets are intangible assets in the form of patents, know-how and demonstrated performance. The balance sheet item is recorded at costs incurred and amounts to SEK 43.2 million. The Board is of the opinion that the fair value is clearly higher. The comparisons we made with other companies' intellectual property and development support this assumption.

Outlook

The spread of COVID-19 affects the entire world. Viral disease from China has evolved into a global pandemic and in addition to the life-threatening conditions that can develop, we are also beginning to see the economic effects on the global economy that follow the path of the disease. Due to the spread of infection, this will entail more drawn-out processes for our business, which mainly consists of dialogues with companies based in Asia and the USA.

Despite the general world concern about the spread of the corona virus, the company has stable market prospects. Partly in combination with recently concluded licensing deals, and partly with achieved successes in the development work where it is becoming increasingly clear that Smoltek's pioneering CNF-MIM technology addresses

current needs in the ever-growing market for high-performance semiconductor circuits. The important work of building relationships and deepening interactions with most of the leading industrial players in the US and Asia continues. At the same time, the Company continues its determined efforts to develop the patent portfolio.

Accounting

This report has been prepared in accordance with the Swedish Annual Accounts Act and the Accounting Committee's General Council, BFNAR 2012: 1 (K3) and the accounting principles are unchanged compared with the previous year.

Annual Report and Annual General Meeting

The annual report is published on April 23, 2020 on the company's website and news.cision.com/se/?q=Smoltek.

On request to info@smoltek.com a printed version of the annual report can be sent. The Annual General Meeting for the 2019 financial year has been postponed for the time being, however it will be held in Gothenburg, before the end of June 2020. Notice of the meeting will be published on www.smoltek.com and announced in Post och Inrikes Tidningar (The Official Gazette) and Dagens Industri, no later than four weeks before the meeting.

Risks and uncertainties

Smoltek Nanotech Holding AB's earnings and financial position are affected by various risk factors that must be taken into account when assessing the company and its future potential. These risks are discussed in the 2019 annual report.

Consolidated income statement

Smoltek Nanotech Holding AB incl. subsidiaries

(SEK thousand)

| | Jan-Mar 2020 | Jan-Mar 2019 | Full year 2019 |
|--|---------------|---------------|----------------|
| Net sales | 384 | 0 | 506 |
| Own work capitalized | 1,291 | 806 | 3,962 |
| Other operating income | 8 | 0 | 0 |
| Operating expenses | -5,674 | -3,547 | -17,016 |
| Operating profit/loss | -3,991 | -2,741 | -12,548 |
| Profit/loss from financial items | 0 | 0 | -16 |
| Profit/loss for the period | -3,991 | -2,741 | -12,564 |
| Profit/loss after tax per share | -0.63 | -0.52 | -2.06 |

Consolidated balance sheet

Smoltek Nanotech Holding AB incl. subsidiaries

(SEK thousand)

| | 2020-03-31 | 2019-03-31 | 2019-12-31 |
|-------------------------------------|---------------|---------------|---------------|
| <i>Assets</i> | | | |
| Intangible fixed assets | 43,195 | 35,398 | 41,068 |
| Tangible fixed assets | 1,008 | 1,008 | 1,008 |
| Current receivables | 1,496 | 1,156 | 1,822 |
| Cash and cash equivalents | 22,818 | 1,893 | 24,642 |
| Total assets | 65,518 | 39,455 | 68,540 |
| <i>Equity and liabilities</i> | | | |
| Equity | 63,754 | 35,795 | 63,481 |
| Long-term liabilities | 819 | 837 | 819 |
| Current liabilities | 3,945 | 2,823 | 4,240 |
| Total equity and liabilities | 68,518 | 39,455 | 68,540 |
| Equity/assets ratio | 93.0% | 90.7% | 92.6% |

Consolidated statement of cash flows

Smoltek Nanotech Holding AB incl. subsidiaries

(SEK thousand)

| | Jan-Mar 2020 | Jan-Mar 2019 | Full year 2019 |
|--|---------------|---------------|----------------|
| Ongoing operations | | | |
| Operating profit/loss | -3,991 | -2,740 | -12,548 |
| Profit/loss from financial items | 0 | -1 | -16 |
| Cash flow from operating activities before changes in working capital | -3,991 | -2,741 | -12,564 |
| Changes in working capital | | | |
| Change in receivables | 326 | -532 | -1,198 |
| Changes in current liabilities | -295 | 370 | 1,848 |
| Changes in current liabilities | -3,960 | -2,903 | -11,914 |
| Investment activities | | | |
| Intangible assets | -2,127 | -1,300 | -6,969 |
| Cash flow from investment activities | -2,127 | -1,300 | -6,969 |
| Financing activities | | | |
| Rights issue | 4,264 | 0 | 37,173 |
| Expenditure on raising capital | 0 | -277 | 0 |
| Change in long-term liabilities | 0 | 0 | -19 |
| Cash flow from financing activities | 4,264 | -277 | 37,154 |
| Change in cash and cash equivalents | -1,823 | -4,479 | 18,270 |
| Cash opening balance | 24,642 | 6,372 | 6,372 |
| Cash closing balance | 22,818 | 1,893 | 24,642 |

Consolidated changes in equity

Smoltek Nanotech Holding AB incl. subsidiaries

(SEK thousand)

| | Share capital | Unregistered share capital | Other contributed capital | Other equity including net loss for the period | Total equity |
|-----------------------------------|---------------|----------------------------|---------------------------|--|---------------|
| Opening balance 2020-01-01 | 760 | | 81,314 | -18,592 | 63,481 |
| Issue of warrants Smoltek AB | | 51 | 4,213 | | 4,264 |
| Profit/loss for the period | | | | -3,991 | -3,991 |
| Closing balance 2020-03-31 | 760 | 51 | 85,527 | -22,583 | 63,754 |

Parent company income statement

Smoltek Nanotech Holding AB

(SEK thousand)

| | Jan-Mar 2020 | Jan-Mar 2019 | Full year 2019 |
|-----------------------------------|---------------------|---------------------|-----------------------|
| Net sales | 625 | 625 | 2,500 |
| Operating expenses | -1,024 | -859 | -3,914 |
| Operating profit/loss | -399 | -234 | -1,414 |
| Profit/loss from financial items | 157 | 95 | 586 |
| Profit/loss for the period | -242 | -139 | -828 |

Parent company balance sheet

Smoltek Nanotech Holding AB

(SEK thousand)

| | 2020-03-31 | 2019-03-31 | 2019-12-31 |
|--|---------------|---------------|---------------|
| <i>Assets</i> | | | |
| Shares in group companies | 42,999 | 32,999 | 42,999 |
| Long-term receivables at group companies | 34,117 | 25,292 | 29,923 |
| Current receivables | 973 | 305 | 295 |
| Cash and cash equivalents | 17,477 | 460 | 22,725 |
| Total assets | 95,567 | 59,057 | 95,942 |
| <i>Equity and liabilities</i> | | | |
| Equity | 94,658 | 58,139 | 94,900 |
| Current liabilities | 909 | 918 | 1,042 |
| Total equity and liabilities | 95,567 | 59,057 | 95,942 |
| Equity/assets ratio | 99.0% | 98.4% | 98.9% |

Parent company statement of cash flows

Smoltek Nanotech Holding AB

(SEK thousand)

| | Jan-Mar 2020 | Jan-Mar 2019 | Full year 2019 |
|--|---------------|---------------|----------------|
| Ongoing operations | | | |
| Operating profit/loss | -399 | -234 | -1,414 |
| Profit/loss from financial items | 0 | 0 | -1 |
| Cash flow from operating activities before changes in working capital | -399 | -234 | -1,415 |
| Changes in working capital | | | |
| Change in receivables | -679 | -213 | -235 |
| Changes in current liabilities | -133 | 203 | 359 |
| Cash flow from operating activities | -1,211 | -244 | -1,291 |
| Investment activities | | | |
| Financial assets | 0 | -50 | -50 |
| Changes in receivables from group companies | -4,038 | -4,686 | -18,825 |
| Cash flow from investment activities | -4,038 | -4,736 | -18,875 |
| Financing activities | | | |
| Rights issue | 0 | 0 | 37,173 |
| Expenditure on raising capital | 0 | -277 | 0 |
| Cash flow from financing activities | 0 | -277 | 37,154 |
| Change in cash and cash equivalents | -5,248 | -5,258 | 17,007 |
| Cash opening balance | 22,725 | 5,718 | 5,718 |
| Cash closing balance | 17,477 | 460 | 22,725 |

Parent company changes in equity

Smoltek Nanotech Holding AB

(SEK thousand)

| | Restricted equity | Non-restricted equity | Total equity |
|-----------------------------------|------------------------------|----------------------------------|-------------------------|
| Opening balance 2020-01-01 | 760 | 94,140 | 94,900 |
| Profit/loss for the period | | -242 | -242 |
| Closing balance 2020-03-31 | 760 | 93,898 | 94,658 |

Financial Calendar

- The Annual report for 2019 will be published on 2020-04-23
- The Interim report for Q2, 2020, will be published on 2020-07-16
- The Interim report for Q3, 2020, will be published on 2020-10-29

Auditor review

The Interim report has not been reviewed by the company's auditors.

Smoltek Nanotech Holding AB is listed on Spotlight Stock Market since 2018-02-26 under the short name SMOL.

For further information:

Anders Johansson, CEO Smoltek Nanotech Holding AB

E-Mail: anders@smoltek.com

Telephone: 0708-393 693

Website: www.smoltek.com

Göteborg 2020-04-20

The Board





Smoltek Nanotech Holding AB

Kaserntorget 7, 411 18 Göteborg
0760-52 00 53 | info@smoltek.com
www.smoltek.com

Corporate id: 559020-2262

